Open Access Open Access  Restricted Access Subscription Access

An Effect of Endonetrial Cancer Regarding Pathophysiology, Diagnosis and Treatment

Srinivas G., Ramanjaneyulu D. V., Muralinath E., Guruprasad M., Sravani Pragna K., Manjari P., Sony Sharlet E., T. Nikhil, V.Yaswanth Sai, D. Kusuma Latha, R. Faith Rani, P. Megha Varna, Sahil Manoranjan

Abstract


Endometrial cancer is a malignancy appearing within the epithelial lining of the uterus. Endometrial cancer is the most prevalent gynecologic malignancy in American women and a significant cause of morbidity and mortality. Over 66,000 new cases were expected in 2023; therefore, clinicians must be equipped with the necessary clinical knowledge to diagnose patients presenting with symptoms namely abnormal uterine bleeding, pelvic pain, or uterine enlargement—common manifestations of this condition. Diagnosing endometrial cancer needs understanding the suggestions particularly for endometrial biopsy, different sampling techniques, and the role of imaging studies in staging and assessing metastases. Managing endometrial cancer comprises surgical staging, adjuvant therapies along with radiation therapy, chemotherapy, hormone therapy, and targeted therapy and post treatment monitoring for recurrence.This course envelops diagnostic techniques, treatment modalities, and post-treatment monitoring for endometrial cancer. The difficult and intricate nature of treating this illness is also acknowledged in this course, emphasizing the value of an interprofessional team approach in improving patient outcomes and reducing the burden of endometrial cancer. Interprofessional collaboration helps participants explore the best ways to care for patients, improve their ability to navigate the complexity of endometrial cancer, and promote treatment through coordinated, all-encompassing efforts across healthcare disciplines.


Full Text:

PDF

References


Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17-48.

Creasman, W. T., Odicino, F., Maisonneuve, P., Quinn, M. A., Beller, U., Benedet, J. L., Heintz, A., Ngan, H., & Pecorelli, S. (2006). Carcinoma of the corpus uteri. International Journal of Gynaecology and Obstetrics, 95(Suppl 1), S105-S143.

Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. L. (2019). Current recommendations and recent progress in endometrial cancer. CA: A Cancer Journal for Clinicians, 69(4), 258-279.

Feinberg, J., Albright, B., Black, J., Lu, L., Passarelli, R., Gysler, S., Whicker, M., Altwerger, G., Menderes, G., Hui, P., Santin, A. D., Azodi, M., Silasi, D. A., Ratner, E. S., Litkouhi, B., & Schwartz, P. E. (2019). Ten-year comparison study of type 1 and 2 endometrial cancers: Risk factors and outcomes. Gynecologic and Obstetric Investigation, 84(3), 290-297.

Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021). Endometrial cancer. Nature Reviews Disease Primers, 7(1), 88.

Liu, L., Habeshian, T. S., Zhang, J., Peeri, N. C., Du, M., De Vivo, I., & Setiawan, V. W. (2023). Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. JNCI Cancer Spectrum, 7(1).

Smrz, S. A., Calo, C., Fisher, J. L., & Salani, R. (2021). An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. American Journal of Obstetrics and Gynecology, 224(5), 506.e1-506.e8.

Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., Ledermann, J. A., & ESMO Guidelines Committee. (2022). Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Annals of Oncology, 33(9), 860-877.

Gordhandas, S., Zammarrelli, W. A., Rios-Doria, E. V., Green, A. K., & Makker, V. (2023). Current evidence-based systemic therapy for advanced and recurrent endometrial cancer. Journal of the National Comprehensive Cancer Network, 21(2), 217-226.

Daniilidis, A., Margioula-Siarkou, C., Margioula-Siarkou, G., Papandreou, P., Papanikolaou, A., Dinas, K., & Petousis, S. (2022). Sentinel lymph node mapping in endometrial cancer to reduce surgical morbidity: Always, sometimes, or never. Przegląd Menopauzalny, 21(3), 207-213.

Casey, M. J., Bewtra, C., Lynch, H. T., Snyder, C. L., & Stacey, M. (2015). Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: Report from the Creighton University Hereditary Cancer Registry with review of the implications. International Journal of Gynecological Cancer, 25(4), 650-656.

Hoang, L. N., Han, G., McConechy, M., Lau, S., Chow, C., Gilks, C. B., Huntsman, D. G., Köbel, M., & Lee, C. H. (2014). Immunohistochemical characterization of prototypical endometrial clear cell carcinoma: Diagnostic utility of HNF-1β and estrogen receptor. Histopathology, 64(4), 585-596.

Lim, D., Murali, R., Murray, M. P., Veras, E., Park, K. J., & Soslow, R. A. (2016). Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors. American Journal of Surgical Pathology, 40(3), 302-312.

Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N., Crum, C. P., & Meserve, E. E. (2015). Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. American Journal of Surgical Pathology, 39(3), 287-293.

Casey, M. J., & Colanta, A. B. (2016). Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: Implications for risk-reducing surgery. Family Cancer, 15(3), 371-384.

Paleari, L., Pesce, S., Rutigliani, M., Greppi, M., Obino, V., Gorlero, F., & Vellone, V. G. (2021). New insights into endometrial cancer. Cancers (Basel), 13(7).

Chelmow, D., Brooks, R., Cavens, A., Huber-Keener, K., Scott, D. M., Sheth, S. S., Whetstone, S., Worly, B., & Burke, W. (2022). Executive summary of the Uterine Cancer Evidence Review Conference. Obstetrics and Gynecology, 139(4), 626-643.

Berek, J. S., Matias-Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., & Concin, N. (2023). FIGO staging of endometrial cancer: 2023. International Journal of Gynaecology and Obstetrics, 162(2), 383-394.

Murali, R., Davidson, B., Fadare, O., Carlson, J. A., Crum, C. P., Gilks, C. B., Irving, J. A., Malpica, A., Matias-Guiu, X., McCluggage, W. G., Mittal, K., Oliva, E., Parkash, V., Rutgers, J. K. L., Staats, P. N., Stewart, C. J. R., Tornos, C., & Soslow, R. A. (2019). High-grade endometrial carcinomas: Morphologic and immunohistochemical features, diagnostic challenges, and recommendations. International Journal of Gynecological Pathology, 38(Suppl 1), S40-S63.

Lax, S. F., Kurman, R. J., Pizer, E. S., Wu, L., & Ronnett, B. M. (2000). A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advanced-stage tumors with favorable and unfavorable prognosis. American Journal of Surgical Pathology, 24(9), 1201-1208.


Refbacks

  • There are currently no refbacks.